We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to...
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its...
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following...
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.05 | 2.84090909091 | 1.76 | 1.87 | 1.65 | 265660 | 1.7368738 | CS |
| 4 | 0.14 | 8.38323353293 | 1.67 | 1.95 | 1.65 | 256410 | 1.76683029 | CS |
| 12 | -0.15 | -7.65306122449 | 1.96 | 2.43 | 1.65 | 312027 | 1.96913627 | CS |
| 26 | 0.03 | 1.68539325843 | 1.78 | 3.1399 | 1.62 | 257307 | 2.06793838 | CS |
| 52 | -2.9 | -61.5711252654 | 4.71 | 5.7 | 1.62 | 207476 | 2.57913215 | CS |
| 156 | -17.79 | -90.7653061224 | 19.6 | 23.96 | 1.62 | 153886 | 6.17274132 | CS |
| 260 | -40.21 | -95.6925273679 | 42.02 | 63.62 | 1.62 | 161432 | 10.37345476 | CS |
PonkenPlonken
3 weeks ago
Monksdream
2 months ago
glenn1919
2 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
